SCYNEXIS Net Loss Widens Amid Revenue Dip, Nasdaq Delisting Threat Looms

TL;DR

**SCYX is bleeding cash and facing a Nasdaq delisting, making it a high-risk bet despite promising drug pipeline.**

AI Summary

SCYNEXIS INC (SCYX) reported a net loss of $8.59 million for the three months ended September 30, 2025, a significant increase from the $2.81 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $20.87 million, up from $16.86 million in 2024. License agreement revenue decreased to $334,000 for the three months ended September 30, 2025, from $660,000 in 2024, and to $1.96 million for the nine months ended September 30, 2025, from $2.77 million in 2024. Research and development expenses declined to $5.45 million for the three months ended September 30, 2025, from $8.07 million in 2024, and to $17.74 million for the nine months ended September 30, 2025, from $22.09 million in 2024. Selling, general and administrative expenses increased to $3.29 million for the three months ended September 30, 2025, from $2.91 million in 2024. The company's cash and cash equivalents, along with investments, totaled $37.9 million as of September 30, 2025, down from $59.2 million at December 31, 2024. SCYNEXIS also faces a Nasdaq minimum bid price compliance issue, with a deadline of December 17, 2025, to regain compliance. The company paid off $14.0 million in convertible debt during the nine months ended September 30, 2025.

Why It Matters

SCYNEXIS's widening net loss and declining revenue are critical for investors, signaling increased financial pressure and potential dilution. The Nasdaq minimum bid price notification, with a December 17, 2025, compliance deadline, adds significant uncertainty, potentially impacting investor confidence and stock liquidity. For employees, continued financial strain could lead to job insecurity or reduced R&D investment, affecting the development of promising drugs like SCY-247. Customers relying on BREXAFEMME or future fungerps might see slower innovation if financial woes persist. Competitively, SCYNEXIS's struggles could allow rivals to gain market share in the antifungal space, especially given the company's focus on drug-resistant infections.

Risk Assessment

Risk Level: high — The company reported an accumulated deficit of $397.4 million as of September 30, 2025, and a net loss of $20.87 million for the nine months ended September 30, 2025. Furthermore, SCYNEXIS received a Nasdaq minimum bid price notification on June 20, 2025, indicating its common stock was below the $1.00 per share minimum, with a compliance deadline of December 17, 2025.

Analyst Insight

Investors should exercise extreme caution and consider divesting if they are risk-averse, given the widening losses and Nasdaq compliance risk. Those with a high-risk tolerance might monitor for positive developments in SCY-247 clinical trials or a resolution to the Nasdaq issue, but significant downside risk remains.

Financial Highlights

debt To Equity

N/A

revenue

$334,000

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$8.59 million

eps

N/A

gross Margin

N/A

cash Position

$37.9 million

revenue Growth

-49.4%

Revenue Breakdown

Key Numbers

• $8.59M — Net loss for Q3 2025 (Increased from $2.81M in Q3 2024)
• $20.87M — Net loss for nine months ended Sept 30, 2025 (Increased from $16.86M in 2024)
• $334K — License agreement revenue for Q3 2025 (Decreased from $660K in Q3 2024)
• $1.96M — License agreement revenue for nine months ended Sept 30, 2025 (Decreased from $2.77M in 2024)
• $5.45M — Research and development expenses for Q3 2025 (Decreased from $8.07M in Q3 2024)
• $17.74M — Research and development expenses for nine months ended Sept 30, 2025 (Decreased from $22.09M in 2024)
• $3.29M — Selling, general and administrative expenses for Q3 2025 (Increased from $2.91M in Q3 2024)
• $37.9M — Cash and cash equivalents and investments as of Sept 30, 2025 (Down from $59.2M at Dec 31, 2024)
• $397.4M — Accumulated deficit as of Sept 30, 2025 (Indicates significant historical losses)
• $14.0M — Convertible debt paid (Paid during the nine months ended Sept 30, 2025)

Key Players & Entities

• SCYNEXIS INC (company) — registrant
• Nasdaq Global Market (regulator) — exchange where SCYX is listed
• GlaxoSmithKline Intellectual Property (No. 3) Limited (company) — licensee of ibrexafungerp
• GSK (company) — licensee of ibrexafungerp
• U.S. Food and Drug Administration (regulator) — approved BREXAFEMME
• FDA (regulator) — approved BREXAFEMME
• Puissance Life Science Opportunities Fund VI (company) — party to March 2019 Note Purchase Agreement
• Brian Feldman (person) — plaintiff in securities class action
• United States District Court, District of New Jersey (regulator) — court for legal proceedings
• Bloomberg (company) — publisher

FAQ

Risk Factors

• Increasing Net Losses [high — financial]: The company reported a net loss of $8.59 million for Q3 2025, a substantial increase from $2.81 million in Q3 2024. The nine-month net loss also grew to $20.87 million from $16.86 million. This trend indicates a worsening financial performance and a growing burn rate.
• Declining Cash Position [high — financial]: Cash and cash equivalents and investments decreased to $37.9 million as of September 30, 2025, from $59.2 million at December 31, 2024. This represents a significant reduction in liquidity, potentially impacting the company's ability to fund operations and future development.
• Nasdaq Minimum Bid Price Non-Compliance [high — regulatory]: SCYNEXIS faces a deadline of December 17, 2025, to regain compliance with Nasdaq's minimum bid price requirement. Failure to do so could result in delisting from the exchange, severely impacting liquidity and investor confidence.
• Decreasing Revenue Streams [medium — financial]: License agreement revenue has declined both quarterly and year-to-date, falling to $334,000 in Q3 2025 from $660,000 in Q3 2024. This reduction in a key revenue source exacerbates the net loss situation.
• Rising SG&A Expenses [medium — operational]: Selling, general, and administrative expenses increased to $3.29 million in Q3 2025 from $2.91 million in Q3 2024. While R&D expenses decreased, the rise in SG&A contributes to the overall increase in net loss.
• Significant Accumulated Deficit [high — financial]: The company has an accumulated deficit of $397.4 million as of September 30, 2025. This highlights a history of unprofitability and a substantial need for future earnings to offset past losses.

Industry Context

SCYNEXIS operates in the biotechnology sector, which is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies in this space often rely on external funding and strategic partnerships to advance their pipelines. The competitive landscape is intense, with many companies vying for breakthroughs in treating infectious diseases.

Regulatory Implications

The company's non-compliance with Nasdaq's minimum bid price requirement poses a significant regulatory risk. Failure to regain compliance by December 17, 2025, could lead to delisting, impacting its ability to raise capital and its overall market standing.

What Investors Should Do

1. Monitor Nasdaq compliance closely.
2. Analyze the burn rate and cash runway.
3. Evaluate the sustainability of R&D spending vs. revenue generation.

Key Dates

• 2025-09-30: End of Q3 2025 — Reporting period for the latest financial results, showing increased net loss and decreased cash.
• 2025-12-17: Nasdaq minimum bid price compliance deadline — Critical date for SCYNEXIS to demonstrate compliance or face potential delisting.
• 2025-09-30: Nine months ended — Period during which $14.0 million in convertible debt was paid off, impacting cash reserves.

Glossary

Accumulated deficit

The total cumulative net losses of a company since its inception, minus any cumulative net income. It represents the total amount of money a company has lost over its lifetime. (Indicates SCYNEXIS's long-term unprofitability, with a deficit of $397.4 million as of September 30, 2025.)

Convertible debt

A type of debt that can be converted into equity (stock) of the issuing company under certain conditions. It offers bondholders the potential to benefit from stock price appreciation. (SCYNEXIS paid off $14.0 million of this debt, impacting its cash position.)

Net loss

The total expenses of a company exceed its total revenues over a specific period, resulting in a negative profit. (SCYNEXIS reported a significant increase in net loss for Q3 2025 ($8.59 million) and the nine-month period ($20.87 million).)

Cash and cash equivalents

Highly liquid short-term investments that can be readily converted into cash. They are crucial for a company's operational liquidity. (SCYNEXIS's cash and equivalents decreased to $37.9 million, raising concerns about its financial runway.)

Year-Over-Year Comparison

Compared to the previous year, SCYNEXIS INC (SCYX) has experienced a significant deterioration in its financial performance. Net losses have widened considerably, with Q3 2025 losses at $8.59 million compared to $2.81 million in Q3 2024. Revenue from license agreements has also decreased, and while R&D expenses have been reduced, SG&A expenses have risen. The company's cash reserves have diminished substantially, and it faces critical regulatory challenges regarding Nasdaq compliance.

Key Financial Figures

• $0.001 — ch Registered Common Stock, par value $0.001 per share SCYX Nasdaq Global Market

Filing Documents

• scyx-20250930.htm (10-Q) — 1879KB
• scyx-ex31_1.htm (EX-31.1) — 18KB
• scyx-ex31_2.htm (EX-31.2) — 19KB
• scyx-ex32_1.htm (EX-32.1) — 12KB
• 0001178253-25-000010.txt ( ) — 8625KB
• scyx-20250930.xsd (EX-101.SCH) — 880KB
• scyx-20250930_htm.xml (XML) — 2041KB

FINANCIAL INFORMATION

PART I FINANCIAL INFORMATION 1 Item 1.

Financial Statements

Financial Statements 1 Unaudited Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 1 Unaudited Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2025 and 2024 2 Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 3 Notes to the Condensed Consolidated Financial Statements (unaudited) 4 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 14 Item 4.

Controls and Procedures

Controls and Procedures 22

OTHER INFORMATION

PART II OTHER INFORMATION 22 Item 1.

Legal Proceedings

Legal Proceedings 22 Item 6. Exhibits 23

Signatures

Signatures 24 Table of Contents

FINANCI AL INFORMATION

PART I. FINANCI AL INFORMATION

Financ ial Statements

Item 1. Financ ial Statements. SCYNEXIS, INC. UNAUDITED CONDENS ED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) September 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 14,797 $ 16,051 Short-term investments 23,131 43,249 Prepaid expenses and other current assets 686 2,184 License agreement receivable 10,000 753 License agreement contract asset — 9,509 Restricted cash 80 435 Total current assets 48,694 72,181 Investments — 15,846 Deferred offering costs 417 417 Restricted cash 109 109 Operating lease right-of-use asset 1,851 2,090 Total assets $ 51,071 $ 90,643 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 3,467 $ 4,569 Accrued expenses 2,774 3,793 Deferred revenue, current portion 1,765 1,642 Operating lease liability, current portion 463 407 Convertible debt — 13,688 Total current liabilities 8,469 24,099 Deferred revenue 807 1,294 Warrant liability 3,544 7,998 Operating lease liability 1,821 2,175 Total liabilities 14,641 35,566 Commitments and contingencies Stockholders' equity: Preferred stock, $ 0.001 par value, authorized 5,000,000 shares as of September 30, 2025 and December 31, 2024; 0 shares issued and outstanding as of September 30, 2025 and December 31, 2024 — — Common stock, $ 0.001 par value, 150,000,000 shares authorized as of September 30, 2025 and December 31, 2024; 41,956,724 and 37,973,991 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 45 41 Additional paid-in capital 433,787 431,571 Accumulated deficit ( 397,402 ) ( 376,535 ) Total stockholders' equity 36,430 55,077 Total liabilities and stockholders' equity $ 51,071 $ 90,643 The accompanying notes are an integral part of the financial statements. 1

Legal Proceedings

Legal Proceedings On November 7, 2023, a securities class action was filed by Brian Feldman against the Company and certain of the Company's executives in the United States District Court, District of New Jersey, alleging misstatements from March 31, 2023 to September 22, 2023 regarding manufacturing controls and related risks. The court granted the Company's motion to dismiss with leave to amend on July 30, 2025, and on August 29, 2025, the parties stipulated to dismissal and the court dismissed the case with prejudice. On May 1, 2024 and on June 4, 2024, purported shareholder derivative complaints asserting related claims were filed in the same court and later consolidated. On October 15, 2025, the court dismissed without prejudice the related consolidated shareholder derivative action. For additional information regarding the details of the securities class action and the consolidated shareholder derivative action, see Item 1 in the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025 filed on August 13, 2025. March 2019 Note Purchase Agreement On March 7, 2019 , the Company entered into a Senior Convertible Note Purchase Agreement (the "March 2019 Note Purchase Agreement") with Puissance Life Science Opportunities Fund VI (" Puissance"). Pursuant to the March 2019 Note Purchase Agreement, on March 7, 2019, the Company issued and sold to Puissance $ 16.0 million aggregate principal amount of its 6.0% Senior Convertible Notes due 2025 ("March 2019 Notes"), resulting in $ 14.7 million in net proceeds after deducting $ 1.3 million for an advisory fee and other issuance costs. In April 2019, Puissance converted $ 2.0 million of the March 2019 Notes for 162,600 shares of common stock. The March 2019 Notes matured on March 15, 2025 and the Company repaid the $ 14.0 million due to Puissance. 7. Stockholders' Equity Authorized, Issued, and Outstanding Common Stock The Company's authorized common stock has a par value of $ 0.0

View Full Filing

View this 10-Q filing on SEC EDGAR